# OnCo record herizon-btc-302 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/herizon-btc-302/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "herizon-btc-302", "NCT06282575" ;
  schema:name "HERIZON-BTC-302"@en ;
  schema:description "Tests whether the HER2 bispecific antibody should be given from the start in HER2-positive bile duct cancer."@en ;
  schema:url <https://onco.cc/trials/herizon-btc-302/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06282575>, <https://www.ccanewsonline.com/issues/2026/march-2026-vol-7-no-1/zanidatamab-improves-survival-outcomes-in-her2-positive-biliary-tract-cancer-post-hoc-herizon-btc-01-analysis> ;
  onco:status "recruiting" ;
  onco:phase "3" ;
  schema:startDate "2024-07-19" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:companies <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/zymeworks/> .